Group 1 - The core focus of the company is on the research and development of circular RNA drugs, positioning itself as a high-tech enterprise in the nucleic acid drug sector [1] - The company has established partnerships with leading global firms such as Agilent, Thermo Fisher, and Merck to drive innovation from drug development to industrialization [1] - Currently, the company has seven research pipelines, including ODC drugs for tumors and immune therapy antibody drugs, with some pipelines already entering preclinical research stages [1] Group 2 - The company plans to expand its research pipelines to ten by the end of the year and has initiated preparations for business development transactions [1]